Table 1.
Baseline clinical and pathological characteristics.
| Characteristics | TotalN = 387 (%) | HomoN = 294 (%) | HeteroN = 93 (%) | p-value |
|---|---|---|---|---|
| Age (y/o) | 55 (46–64) | 55 (46–64) | 55 (47–65) | 0.619 |
| Menstrual status | 0.538 | |||
| Pre/Peri- | 160 (41.5) | 124 (42.3) | 36 (38.7) | |
| Post- | 226 (58.5) | 169 (57.7) | 57 (51.3) | |
| Number of foci | 0.378 | |||
| 2 | 354 (91.5) | 271 (92.2) | 83 (89.2) | |
| 3/4 | 33 (8.5) | 23 (7.8) | 10 (10.8) | |
| Location of foci | 0.842 | |||
| Multifocal | 253 (65.4) | 193 (65.6) | 60 (64.5) | |
| Multicentric | 134 (34.6) | 101 (34.4) | 33 (35.5) | |
| Breast surgery | 0.727 | |||
| BCS | 34 (8.8) | 25 (8.5) | 9 (9.7) | |
| Mastectomy | 353 (91.2) | 269 (91.5) | 84 (90.3) | |
| Axillary surgery | 0.733 | |||
| SLNB | 115 (31.3) | 89 (30.9) | 26 (32.9) | |
| ALND | 252 (68.7) | 199 (69.1) | 53 (67.1) | |
| Pathological type a | 0.656 | |||
| IDC | 310 (80.1) | 237 (80.6) | 73 (78.5) | |
| Non-IDC | 77 (19.9) | 57 (19.4) | 20 (21.5) | |
| Pathological type b | <0.001 | |||
| IDC | 247 (63.8) | 211 (71.8) | 36 (38.7) | |
| Non-IDC | 140 (36.2) | 83 (28.2) | 57 (61.3) | |
| Tumor size a | 0.754 | |||
| ≤2.0 cm | 236 (61.0) | 178 (60.5) | 58 (62.4) | |
| >2.0 cm | 151 (39.0) | 116 (39.5) | 35 (37.6) | |
| ALN status | 0.521 | |||
| Negative | 243 (62.8) | 182 (61.9) | 61 (65.5) | |
| Positive | 144 (37.2) | 112 (38.1) | 32 (34.4) | |
| Histological grade a | 0.739 | |||
| I | 24 (6.2) | 20 (6.8) | 4 (4.3) | |
| II | 183 (47.3) | 141 (48.0) | 42 (45.2) | |
| III | 96 (24.8) | 71 (24.1) | 25 (26.9) | |
| NA | 84 (21.7) | 62 (21.1) | 22 (23.6) | |
| Molecular subtype a | <0.001 | |||
| LA | 117 (30.2) | 103 (35.0) | 14 (15.1) | |
| LB (HER2−) | 135 (34.9) | 87 (29.6) | 48 (51.6) | |
| LB (HER2+) | 50 (12.9) | 34 (11.6) | 16 (17.2) | |
| HER2+ | 47 (12.1) | 39 (13.3) | 8 (8.6) | |
| TNBC | 38 (9.9) | 31 (10.5) | 7 (7.5) |
a
Main focus.
b
Minor focus.
ALN, axillary lymph node; ALND, axillary lymph node dissection; BCS, breast-conserving surgery; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; LA, Luminal A-like; LB, Luminal B-like; NA, not available; SLNB, sentinel lymph node biopsy; TNBC, triple negative breast cancer; y/o, years old.